FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1503516375> ?p ?o ?g. }

• W1503516375 abstract "Evolution of therapeutic monoclonal antibodies significantly benefited from the recombinant DNA technologies that are used to generate chimeric, humanized, and human versions of monoclonal antibody to reduce the problem of immunogenicity and neutralization, as well as from understanding mechanisms of action mediated by monoclonal antibodies (Nelson et al., 2010; Reichert, 2009; Ranson & Sliwkowski , 2002). One of the significant advances in the application of monoclonal antibodies in oncology was the introduction and approval of trastuzumab, a humanized anti-HER2 antibody, for the treatment of HER2-positive breast cancer. Despite initial successes and encouraging results, development of monoclonal antibody-based therapies faces several challenges (Yan et al., 2009). Among them are the selection of patients most likely to benefit from clinical trials and lack of understanding of mechanisms of resistance to monoclonal antibody-based therapies (Yan et al., 2009). Selection of patients most likely to benefit from clinical trials of monoclonal antibody-based therapies was initially based on the expression of the antigen targeted by the monoclonal antibody. The anti-HER-2 antibody trastuzumab was tested in patients whose breast tumors overexpress HER2 (Pegram et al., 1998) and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab was used in patients with colorectal cancer and head and neck cancers that overexpress EGFR (Shin et al., 2001). Even with careful characterization of the antigen expression level in the patient population eligible for the clinical trials, primary resistance to monoclonal antibodybased therapies is a common problem. Up to 50% of EGFR-positive colorectal cancer patients are resistant to cetuximab (Saltz et al., 2004), and 74% of HER2-positive breast cancer patients are resistant to anti-HER2 antibody trastuzumab (Vogel et al., 2002). It has emerged that the levels of antigen expression are not the only determinant of the patient response to monoclonal antibody therapies and that better understanding of the mechanisms of resistance to monoclonal antibodies in different patient subgroups has a potential to improve the effectiveness of the monoclonal antibody treatment. A retrospective analysis of the colorectal tumor samples from the patients that received cetuximab therapy indicated that EGFR-positive colorectal cancer patients with wild-type KRAS gene had increased overall" @default.
• W1503516375 created "2016-06-24" @default.
• W1503516375 creator A5062949690 @default.
• W1503516375 creator A5091748729 @default.
• W1503516375 date "2011-11-30" @default.
• W1503516375 modified "2023-10-04" @default.
• W1503516375 title "Trastuzumab-Resistance and Breast Cancer" @default.
• W1503516375 cites W1506855898 @default.
• W1503516375 cites W1518945847 @default.
• W1503516375 cites W155933052 @default.
• W1503516375 cites W1755920412 @default.
• W1503516375 cites W176993554 @default.
• W1503516375 cites W1772131958 @default.
• W1503516375 cites W1836239578 @default.
• W1503516375 cites W1839381104 @default.
• W1503516375 cites W1848910860 @default.
• W1503516375 cites W1933350662 @default.
• W1503516375 cites W1963804483 @default.
• W1503516375 cites W1963858122 @default.
• W1503516375 cites W1964321121 @default.
• W1503516375 cites W1966598152 @default.
• W1503516375 cites W1966937303 @default.
• W1503516375 cites W1967226516 @default.
• W1503516375 cites W1968590850 @default.
• W1503516375 cites W1969345980 @default.
• W1503516375 cites W1970136142 @default.
• W1503516375 cites W1971267920 @default.
• W1503516375 cites W1972648135 @default.
• W1503516375 cites W1973248233 @default.
• W1503516375 cites W1974024530 @default.
• W1503516375 cites W1976408226 @default.
• W1503516375 cites W1981108516 @default.
• W1503516375 cites W1982210988 @default.
• W1503516375 cites W1984000380 @default.
• W1503516375 cites W1984007340 @default.
• W1503516375 cites W1986291899 @default.
• W1503516375 cites W1989506923 @default.
• W1503516375 cites W1990918503 @default.
• W1503516375 cites W1991656907 @default.
• W1503516375 cites W1993804787 @default.
• W1503516375 cites W2001447115 @default.
• W1503516375 cites W2002226820 @default.
• W1503516375 cites W2002228258 @default.
• W1503516375 cites W2002937040 @default.
• W1503516375 cites W2004490932 @default.
• W1503516375 cites W2004492241 @default.
• W1503516375 cites W2004774286 @default.
• W1503516375 cites W2006174096 @default.
• W1503516375 cites W2014111401 @default.
• W1503516375 cites W2014390504 @default.
• W1503516375 cites W2017081079 @default.
• W1503516375 cites W2018204057 @default.
• W1503516375 cites W2020372547 @default.
• W1503516375 cites W2020555298 @default.
• W1503516375 cites W2024651005 @default.
• W1503516375 cites W2027684043 @default.
• W1503516375 cites W2029790859 @default.
• W1503516375 cites W2030177226 @default.
• W1503516375 cites W2030754505 @default.
• W1503516375 cites W2033595975 @default.
• W1503516375 cites W2034091339 @default.
• W1503516375 cites W2034609970 @default.
• W1503516375 cites W2039628288 @default.
• W1503516375 cites W2040142253 @default.
• W1503516375 cites W2053796208 @default.
• W1503516375 cites W2059411043 @default.
• W1503516375 cites W2059625655 @default.
• W1503516375 cites W2060517558 @default.
• W1503516375 cites W2065303540 @default.
• W1503516375 cites W2065725840 @default.
• W1503516375 cites W2066099870 @default.
• W1503516375 cites W2066217014 @default.
• W1503516375 cites W2068071851 @default.
• W1503516375 cites W2071088480 @default.
• W1503516375 cites W2071289226 @default.
• W1503516375 cites W2075967637 @default.
• W1503516375 cites W2080518844 @default.
• W1503516375 cites W2087909560 @default.
• W1503516375 cites W2089487481 @default.
• W1503516375 cites W2090057677 @default.
• W1503516375 cites W2091229935 @default.
• W1503516375 cites W2092897704 @default.
• W1503516375 cites W2094627540 @default.
• W1503516375 cites W2094665743 @default.
• W1503516375 cites W2095333719 @default.
• W1503516375 cites W2096461956 @default.
• W1503516375 cites W2096721687 @default.
• W1503516375 cites W2097121246 @default.
• W1503516375 cites W2098223440 @default.
• W1503516375 cites W2101253730 @default.
• W1503516375 cites W2101299592 @default.
• W1503516375 cites W2101778620 @default.
• W1503516375 cites W2101824720 @default.
• W1503516375 cites W2103013933 @default.
• W1503516375 cites W2104728809 @default.
• W1503516375 cites W2105196235 @default.
• W1503516375 cites W2108410343 @default.
• W1503516375 cites W2108501693 @default.
• W1503516375 cites W2109189228 @default.
• W1503516375 cites W2112893608 @default.

• next